(Total Views: 562)
Posted On: 07/26/2023 3:24:29 PM
Post# of 154119
Re: jojopaint57 #136222
And Cyrus liked a post by absci on Linkedin. Plus they specialize in antibodies.
But it doesn't really matter what the fundamentals of absci's business is, all that matters is whether their machine learning can improve the drug discovery or modification process.
I'd say we still have a ways to go with the FDA as Antonio mentioned in the call that the company is hard at work repairing that relationship. It's obviously been a delicate situation for new management trying to balance communicating with shareholders against not antagonizing the FDA. Just more evidence how big of a project this turnaround has been, and still is, and how much damage Nader did.
There was criticism about the FDA probably not being a fan of Nader's tactics as far back as 2016 when he went on Dr Oz with Charlie Sheen. That's at least 6 years of exasperation with the FDA that current management is trying to make up for.
But it doesn't really matter what the fundamentals of absci's business is, all that matters is whether their machine learning can improve the drug discovery or modification process.
I'd say we still have a ways to go with the FDA as Antonio mentioned in the call that the company is hard at work repairing that relationship. It's obviously been a delicate situation for new management trying to balance communicating with shareholders against not antagonizing the FDA. Just more evidence how big of a project this turnaround has been, and still is, and how much damage Nader did.
There was criticism about the FDA probably not being a fan of Nader's tactics as far back as 2016 when he went on Dr Oz with Charlie Sheen. That's at least 6 years of exasperation with the FDA that current management is trying to make up for.
(2)
(0)
